Never miss an important update on your stock portfolio and cut through the noise. Over 7 million investors trust Simply Wall St to stay informed where it matters for FREE.
LeMaitre Vascular is back in focus as analysts cluster price targets in the $105 to $117 range, while a fair value estimate of $111.00 remains unchanged. This tight band reflects how recent commentary is leaning on revenue quality, profitability trends, and execution to frame where the stock might reasonably trade. As you read on, you will see how this evolving narrative is taking shape and what to watch if you want to keep up with the next moves in the story.
Stay updated as the Fair Value for LeMaitre Vascular shifts by adding it to your watchlist or portfolio. Alternatively, explore our Community to discover new perspectives on LeMaitre Vascular.
-
Barrington lifted its price target on LeMaitre Vascular to $105, highlighting what it describes as double digit organic revenue growth, margin expansion, and strong cash flow as key supports for that higher range.
-
Roth Capital increased its price target to $117 after what it calls better than expected Q4 results and guidance, pointing to continued sales growth coupled with operating leverage as reasons for its constructive stance.
-
Taken together, the $105 and $117 targets anchor the current cluster near the fair value estimate of $111.00, which places recent execution on growth and profitability at the center of analyst models.
-
With targets already reset higher by Barrington and Roth Capital, some readers may question how much additional upside these firms see from current levels if growth, margins, or cash generation were to come in below their expectations.
-
The focus on operating leverage and margin expansion also means any setback on costs or pricing could challenge the assumptions behind the recent price target increases.
Do your thoughts align with the Bull or Bear Analysts? Perhaps you think there’s more to the story. Head to the Simply Wall St Community to discover more perspectives!
We’ve flagged 1 risk for LeMaitre Vascular. See which could impact your investment.
-
LeMaitre Vascular issued Q1 2026 guidance, calling for sales of US$65.6 million to US$67.6 million, operating income of US$16.7 million to US$18.1 million, and EPS of US$0.64 to US$0.69.
-
Full year 2026 guidance targets sales of US$276 million to US$284 million, operating income of US$75.0 million to US$80.7 million, and diluted EPS of US$2.81 to US$3.01.
-
The Board approved a share repurchase plan on February 19, 2026, authorizing up to US$100 million of common stock buybacks through February 18, 2027, unless extended.
-
The company announced a quarterly dividend of US$0.25 per share payable on March 26, 2026, and reported that no shares were repurchased and no cash was spent in the buyback tranche from October 1, 2025 to December 31, 2025 under the prior program.